![Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01699-1/MediaObjects/41591_2022_1699_Fig1_HTML.png)
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Protection duration after vaccination or infection, and efficacy of a third dose by vaccination or booster by infection – Swiss National COVID-19 Science Task Force Protection duration after vaccination or infection, and efficacy of a third dose by vaccination or booster by infection – Swiss National COVID-19 Science Task Force](https://sciencetaskforce.ch/wp-content/uploads/2021/12/Fig.2-policubrief.jpg)
Protection duration after vaccination or infection, and efficacy of a third dose by vaccination or booster by infection – Swiss National COVID-19 Science Task Force
![Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/21aefd8d-1880-42db-8338-92a386a5842f/gr1.jpg)
Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study - The Lancet Infectious Diseases
![Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post](https://datawrapper.dwcdn.net/cvun1/fallback.png)
Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post
![Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-33169-0/MediaObjects/41467_2022_33169_Fig1_HTML.png)
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | Nature Communications
![JCVI statement on the adult COVID-19 booster vaccination programme and the Omicron variant: 7 January 2022 - GOV.UK JCVI statement on the adult COVID-19 booster vaccination programme and the Omicron variant: 7 January 2022 - GOV.UK](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/139650/jcvi-chart-1-7-jan-22.png)
JCVI statement on the adult COVID-19 booster vaccination programme and the Omicron variant: 7 January 2022 - GOV.UK
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)